PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for presentation at the American Association for Cancer Research ("AACR") Annual Meeting ...
An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...
TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...
Artificial intelligence (AI) could help physicians determine if survivors of childhood cancer need extra support - and the more information included in AI prompting, the better its performance. This ...
Prostate cancer remains one of the most common diseases among men, yet current screening methods often lead to unnecessary ...
A new liquid biopsy test using artificial intelligence models could help spot a rare type of bone and soft tissue cancer that ...
TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food ...
A recent study published in Cell Reports Medicine has identified distinct microbial signatures within the oral cavity and gut ...
The United States Food and Drug Administration (FDA) issued guidance on its “Breakthrough Devices Program” in 2023. The ...
Predicting the uptake of free cancer screening services in rural India using machine learning tools.
This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results